A recent study presented at the Annual Scientific Meeting of the British Blood Transfusion Society, held in Brighton, United Kingdom from October 3-5, 2018, sought to determine the impact of introducing biosimilar filgrastim (sold in the United Kingdom as Zarzio) on the number of patients who were able to achieve target CD34 yield in peripheral blood stem cell mobilization (PBCM).
A recent study presented at the Annual Scientific Meeting of the British Blood Transfusion Society, held in Brighton, United Kingdom from October 3-5, 2018, sought to determine the impact of introducing biosimilar filgrastim (sold in the United Kingdom as Zarzio) on the number of patients who were able to achieve target CD34 yield in peripheral blood stem cell mobilization (PBCM).
Data were collected from 52 patients undergoing PBSC collection at a health system in Edinburgh, Scotland, between March 2017 and February 2018. All patients were mobilized with biosimilar filgrastim subcutaneously at a dose of 5 µL/kg beginning after chemomobilization and continuing until PBSC collection was completed. Stem cell collection was initiated when peripheral blood CD34 cells exceeded 15 µL.
Many different disease states were included within the trial, and the indication for stem cell mobilization included patients with non-Hodgkin lymphoma (n = 24, 46%), multiple myeloma (n = 21, 40%), Hodgkin lymphoma (n = 2, 4%), germ cell tumors (n = 5, 10%).
In total, 71% of patients mobilized with biosimilar filgrastim required only 1 leukapheresis procedure, compared with 50% of patients mobilized with the reference. Additionally, 49% of patients who were mobilized with biosimilar filgrastim achieved their target CD34 yield 24 hours after the planned day of first collection.
Researchers found that biosimilar filgrastim was non-inferior to the reference product in terms of achieving CD34 yield. The study’s authors also noted that delaying the first day of collection by 24 hours may result in a more cost-effective and efficient collection process.
The European market has years of experience with biosimilars. In the European Union, there are currently 7 biosimilar filgrastim options on the market. Conversely, in the United States, biosimilars have only been available since 2015. As such, there are only 2 FDA-approved biosimilar filgrastim products on the market to date.
Reference
Elamin FE, Manson, L. Use of biosimilar filgrastim for peripheral blood stem cell mobilization: a single centre experience in UK. Presented at the Annual Scientific Meeting of the British Blood Transfusion Society October 3-5, 2018, United Kingdom. Abstract PO122. onlinelibrary.wiley.com/doi/epdf/10.1111/tme.12558.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.